Read through the last February Editor's Choice article "Evaluation for genetic disease in kidney transplant candidates: A practice resource" by Ames et al. https://buff.ly/4jLjjdA #riskalleles #genetictesting
#MassGeneral physicians Tatsuo Kawai, MD, and Leo Riella, MD, were featured in @CBSNews's report on MGH's second pig kidney transplant, which they conducted.https://www.cbsnews.com/boston/news/pig-kidney-transplant-massachusetts-general-hospital/
223 lives changed. 75 living kidney donors. 6 satellite locations. 1 mission: pioneering kidney transplant care for all through access and innovation like xenotransplantation and tolerance. #KidneyTransplant Learn more: http://massgeneral.org/kidneytransplant
Mass General set another milestone. Jan 25th marked our 2nd successful xenotransplant of a genetically-edited pig kidney into a living recipient. Tim Andrews is now the 4th person in the world to receive a genetically-edited pig kidney. http://spklr.io/6016F2g0
🚨 Breaking Records Again! 🚨
For 13 years in a row, our transplant teams have saved more lives through #OrganTransplantation than any hospital in New England.
👏 Shoutout to our patients, care teams and researchers for an amazing year in 2024! #TransplantInnovation #DonateLife
1/7 @MGHKidneys @mgh_transplant
🩺 Path case: 50yo male, kidney transplant recipient (6 years post-tx), with a hx of membranous nephropathy now presenting with worsening proteinuria (3.9 g/day) and stable creatinine (0.9 mg/dL).
🔬 DSA: Neg
🧪 Serum PLA2R: Neg
Key learnings!👇
6/7
🔬 Takeaway for Clinical Practice
• Be vigilant for MN recurrence in kidney transplant recipients with prior history.
• Regularly monitor proteinuria and PLA2R antibodies post-transplant.
• Rituximab is an effective Rx option based on recurrence risk & antibody levels.
7/7
💡 Final Thought:
This case highlights the importance of recognizing MN recurrence in transplant patients and the role of targeted therapies like rituximab in improving outcomes. @fervenzafernan1 How often do you see PLA2R MN recurrence with negative serum antiPLA2R Ab?
© 2024 Leo Riella
;